Cargando…

Outcome of transcutaneous retrobulbar injection of liposomal amphotericin B in post-COVID-19 rhino-orbito-cerebral mucormycosis: Our experience

PURPOSE: To assess the outcome and response of transcutaneous retrobulbar injection of amphotericin B (TRAMB) in post-coronavirus disease of 2019 (COVID-19) rhino-orbito-cerebral mucormycosis (ROCM) and to establish a scoring system in guiding treatment modalities. METHODS: An interventional, prospe...

Descripción completa

Detalles Bibliográficos
Autores principales: Ramamurthy, Lakshmi B, Bhandari, Ridhi, Kanakpur, Savitha, Thejaswini, P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9114606/
https://www.ncbi.nlm.nih.gov/pubmed/35225564
http://dx.doi.org/10.4103/ijo.IJO_2356_21
_version_ 1784709815546675200
author Ramamurthy, Lakshmi B
Bhandari, Ridhi
Kanakpur, Savitha
Thejaswini, P
author_facet Ramamurthy, Lakshmi B
Bhandari, Ridhi
Kanakpur, Savitha
Thejaswini, P
author_sort Ramamurthy, Lakshmi B
collection PubMed
description PURPOSE: To assess the outcome and response of transcutaneous retrobulbar injection of amphotericin B (TRAMB) in post-coronavirus disease of 2019 (COVID-19) rhino-orbito-cerebral mucormycosis (ROCM) and to establish a scoring system in guiding treatment modalities. METHODS: An interventional, prospective study was done on 82 eyes of post-COVID-19 ROCM from May 2021 to July 2021. A comprehensive multi-departmental evaluation along with detailed ophthalmic examination, laboratory investigations, and radiological examination was done. Scoring points were given to each symptom, sign, and radiological features of orbit and the total score was taken. Based on these scores, severity of disease was grouped into A, B, and C corresponding to mild, moderate, and severe orbital ROCM. One milliliter of reconstituted liposomal amphotericin B was given to all patients every alternate day as three doses. Efficacy of these injections was assessed in all groups, even though other treatment modalities like orbital debridement and exenteration were considered for moderate and severe cases. Patients were followed up for a period of 8 weeks. RESULTS: Out of 82 eyes, symptomatic improvement was seen in a major proportion (72%) of patients. A statistically significant improvement in scores was noted in group A (93% improved) with a P value of 0.002, while 68.4% showed improvement in group B (P-value- 0.0001). Group C with severe disease showed minimal improvement in post-injection scores of 41% (P-value 0.086), necessitating surgical intervention. No serious adverse effect of the drug or procedure was noted. CONCLUSION: Significant improvement in scores of groups A and B highlights TRAMB as an effective and safe treatment modality in mild to moderate ROCM. It is an effective adjunct in severe cases, along with other interventions. Also, the scoring system helps in assessing the severity and guiding in management strategies.
format Online
Article
Text
id pubmed-9114606
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Wolters Kluwer - Medknow
record_format MEDLINE/PubMed
spelling pubmed-91146062022-05-19 Outcome of transcutaneous retrobulbar injection of liposomal amphotericin B in post-COVID-19 rhino-orbito-cerebral mucormycosis: Our experience Ramamurthy, Lakshmi B Bhandari, Ridhi Kanakpur, Savitha Thejaswini, P Indian J Ophthalmol Expedited Publications, Original Article PURPOSE: To assess the outcome and response of transcutaneous retrobulbar injection of amphotericin B (TRAMB) in post-coronavirus disease of 2019 (COVID-19) rhino-orbito-cerebral mucormycosis (ROCM) and to establish a scoring system in guiding treatment modalities. METHODS: An interventional, prospective study was done on 82 eyes of post-COVID-19 ROCM from May 2021 to July 2021. A comprehensive multi-departmental evaluation along with detailed ophthalmic examination, laboratory investigations, and radiological examination was done. Scoring points were given to each symptom, sign, and radiological features of orbit and the total score was taken. Based on these scores, severity of disease was grouped into A, B, and C corresponding to mild, moderate, and severe orbital ROCM. One milliliter of reconstituted liposomal amphotericin B was given to all patients every alternate day as three doses. Efficacy of these injections was assessed in all groups, even though other treatment modalities like orbital debridement and exenteration were considered for moderate and severe cases. Patients were followed up for a period of 8 weeks. RESULTS: Out of 82 eyes, symptomatic improvement was seen in a major proportion (72%) of patients. A statistically significant improvement in scores was noted in group A (93% improved) with a P value of 0.002, while 68.4% showed improvement in group B (P-value- 0.0001). Group C with severe disease showed minimal improvement in post-injection scores of 41% (P-value 0.086), necessitating surgical intervention. No serious adverse effect of the drug or procedure was noted. CONCLUSION: Significant improvement in scores of groups A and B highlights TRAMB as an effective and safe treatment modality in mild to moderate ROCM. It is an effective adjunct in severe cases, along with other interventions. Also, the scoring system helps in assessing the severity and guiding in management strategies. Wolters Kluwer - Medknow 2022-03 2022-02-25 /pmc/articles/PMC9114606/ /pubmed/35225564 http://dx.doi.org/10.4103/ijo.IJO_2356_21 Text en Copyright: © 2022 Indian Journal of Ophthalmology https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Expedited Publications, Original Article
Ramamurthy, Lakshmi B
Bhandari, Ridhi
Kanakpur, Savitha
Thejaswini, P
Outcome of transcutaneous retrobulbar injection of liposomal amphotericin B in post-COVID-19 rhino-orbito-cerebral mucormycosis: Our experience
title Outcome of transcutaneous retrobulbar injection of liposomal amphotericin B in post-COVID-19 rhino-orbito-cerebral mucormycosis: Our experience
title_full Outcome of transcutaneous retrobulbar injection of liposomal amphotericin B in post-COVID-19 rhino-orbito-cerebral mucormycosis: Our experience
title_fullStr Outcome of transcutaneous retrobulbar injection of liposomal amphotericin B in post-COVID-19 rhino-orbito-cerebral mucormycosis: Our experience
title_full_unstemmed Outcome of transcutaneous retrobulbar injection of liposomal amphotericin B in post-COVID-19 rhino-orbito-cerebral mucormycosis: Our experience
title_short Outcome of transcutaneous retrobulbar injection of liposomal amphotericin B in post-COVID-19 rhino-orbito-cerebral mucormycosis: Our experience
title_sort outcome of transcutaneous retrobulbar injection of liposomal amphotericin b in post-covid-19 rhino-orbito-cerebral mucormycosis: our experience
topic Expedited Publications, Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9114606/
https://www.ncbi.nlm.nih.gov/pubmed/35225564
http://dx.doi.org/10.4103/ijo.IJO_2356_21
work_keys_str_mv AT ramamurthylakshmib outcomeoftranscutaneousretrobulbarinjectionofliposomalamphotericinbinpostcovid19rhinoorbitocerebralmucormycosisourexperience
AT bhandariridhi outcomeoftranscutaneousretrobulbarinjectionofliposomalamphotericinbinpostcovid19rhinoorbitocerebralmucormycosisourexperience
AT kanakpursavitha outcomeoftranscutaneousretrobulbarinjectionofliposomalamphotericinbinpostcovid19rhinoorbitocerebralmucormycosisourexperience
AT thejaswinip outcomeoftranscutaneousretrobulbarinjectionofliposomalamphotericinbinpostcovid19rhinoorbitocerebralmucormycosisourexperience